tert-butyl N-[4-[[2-(5-fluoro-2-methylphenyl)-3,4-dihydro-2H-chromen-6-yl]oxy]cyclohexyl]carbamate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: tert-butyl N-[4-[[2-(5-fluoro-2-methylphenyl)-3,4-dihydro-2H-chromen-6-yl]oxy]cyclohexyl]carbamate
• 化学式: C₂₇H₃₄FNO₄
• 分子量: 455.6
• InChiKey: WDXGUSWWLUFMTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] SUBSTITUTED CHROMAN-6-YLOXY-CYCLOALKANES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] CHROMAN-6-YLOXY-CYCLOALCANES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2014135674A1

  公开（公告）日：2014-09-12

  The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)的取代基氧基环己烷化合物，其中Ar、R1至R4、p和q如权利要求中所定义。式(I)的化合物是钠钙交换体抑制剂（NCX）, 特别是亚型1的钠钙交换体（NCX1）的抑制剂，适用于治疗细胞内钙离子平衡受到干扰的各种疾病，如心律失常、心力衰竭和中风。此外，本发明还涉及制备式(I)的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
  申请人：SANOFI

  公开号：US20160016928A1

  公开（公告）日：2016-01-21

  The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)中的取代的色甘醇-6-氧基环烷烃，其中Ar，R1至R4，p和q如权利要求中所定义。式(I)化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器的亚型1（NCX1），适用于治疗各种细胞内钙平衡紊乱的疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式(I)化合物的方法，它们作为药物的使用以及包含它们的制药组合物。
• SUBSTITUTED CHROMAN-6-YLOXY-CYCLOALKANES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：EP2964623A1

  公开（公告）日：2016-01-13
• US9440941B2
  申请人：——

  公开号：US9440941B2

  公开（公告）日：2016-09-13